Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New glasses aim to halt adult nearsightedness

NCT ID NCT06520124

Disease control Sponsor: University of Ulster Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether Essilor Stellest spectacle lenses can slow the progression of nearsightedness (myopia) in adults aged 18 to 40. Each participant wears a Stellest lens in one eye and a standard lens in the other, allowing direct comparison. The trial measures changes in eye length and prescription over time, and also checks how comfortable adults find the lenses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Essilor Stellest spectacle lens (a lens with tiny lenslets designed to slow eye growth)
What this could lead to
If it works, this could give adults a non-surgical way to slow worsening nearsightedness, reducing future eye health risks.
What could go wrong
This is a small, early-stage trial with only 42 people. The lenses may not work as well in adults as in children, and some people may find them uncomfortable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cycloplegic SER less than -0.75D * Astigmatism of 1.50D or less * Anisometropia of 1.50D or less * Evidence of annual progression of myopia of at least 0.50D in the previous two-year period Exclusion Criteria: * Previous myopia management (other than standard spectacle or contact lens correction) * Ocular and systemic diseases which might affect visual performance or myopia development

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia, progressive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

degenerative myopia myopia refractive error

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia, progressive

Contacts and locations

Locations

  • Ulster University

    Coleraine, County Londonderry, BT52 1SA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.